Physician profile
David A Celko
NPI 1164539920
$11,775.98
in general payments reported to CMS, 2019-2025
49 companies · $153 in 2025
The $153 reported for 2025 was less than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,645 · 2020: $3,916 · 2021: $2,538 · 2022: $698 · 2023: $813 · 2024: $13.64 · 2025: $153.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $979.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $979.37 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $2,629.51 | 2019-2025 | Arexvy, Nucala, Trelegy Ellipta |
| Astrazeneca Pharmaceuticals LP | $1,319.67 | 2019-2023 | |
| Amgen INC. | $984.03 | 2019-2023 | Repatha, Otezla |
| Abbvie INC. | $743.26 | 2019-2023 | Vraylar |
| Jazz Pharmaceuticals INC. | $624.15 | 2019-2021 | |
| Lilly USA, LLC | $616.37 | 2019-2023 | Mounjaro |
| Pfizer INC. | $423.14 | 2019-2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $416.61 | 2019-2024 | Ofev |
| Teva Pharmaceuticals USA, INC. | $362.13 | 2019-2021 | |
| Allergan, INC. | $349.10 | 2019-2020 | |
| Novo Nordisk INC | $292.45 | 2019-2021 | |
| Amarin Pharma, INC. | $265.44 | 2019-2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $264.93 | 2019-2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $253.76 | 2019-2020 | |
| Dermira, INC. | $243.26 | 2019-2021 |
Show all 49 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Celko listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.